文献速递艾滋病与性传播感染

来那帕韦预防HIV感染:当前价格与预估生产成本对比

Lenacapavir to prevent HIV infection: current prices versus estimated costs of production.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

该研究基于原料药出口数据库与合成路线分析,用成本加成模型预估来那帕韦(lenacapavir)仿制药大规模生产的最低价格;在供应100万治疗年时约94美元/人年、1000万治疗年时约41美元/人年,而当前价格为25395至44819美元/人年;实现低价需要自愿许可和多家仿制药供应商竞争,吉利德迄今尚未与药品专利池达成来那帕韦自愿许可。

要点

  • 当前来那帕韦价格为每人每年25395至44819美元,预估大规模生产可低于100美元。
  • 供应100万治疗年时预估约94美元/人年,1000万治疗年时约41美元/人年。
  • 实现低价需自愿许可与多家仿制药供应商竞争,目前尚未达成此类许可。

核心结论

  • 来那帕韦上市时即可通过大规模生产将价格控制在每人每年100美元以下。
  • 实现这些低价需要自愿许可和多家供应商,该机制已在其他抗逆转录病毒药物中应用。
  • 迄今吉利德尚未与药品专利池就来那帕韦达成自愿许可。

研究设计与样本

  • 研究基于出口数据库获取来那帕韦原料药(API)和关键起始物料(KSM)的当前成本。
  • 分析合成路线(ROS)以预估商品成本(COGs),并用标准化算法与成本加成(Cost+)定价纳入制剂、药瓶和利润率成本。
  • 按供应100万和1000万治疗年两种规模预估价格,并与各国目录价格比较。

主要发现

  • 来那帕韦原料药目前以1公斤规模从印度出口,价格为每公斤64480美元。
  • 基于合成路线和关键起始物料,在承诺需求为100万治疗年时可实现原料药商品成本每公斤25000美元,1000万治疗年时为每公斤10000美元。
  • 若存在自愿许可且仿制药供应商间竞争显著改善,包括制剂步骤的注射用来那帕韦在100万治疗年时可大规模生产至约每人每年94美元,1000万治疗年时约41美元。
  • 进一步扩大规模并改进生产商合成路线可进一步降低价格。
  • 当前来那帕韦价格为每人每年25395至44819美元。

关键数值与推荐

  • 当前来那帕韦价格为每人每年25395至44819美元。
  • 供应100万治疗年时预估约每人每年94美元,供应1000万治疗年时约每人每年41美元,前提是存在自愿许可且仿制药供应商间竞争显著改善。
  • 来那帕韦原料药在1公斤规模下从印度出口价格为每公斤64480美元。
  • 基于合成路线和关键起始物料,原料药商品成本在100万治疗年需求时为每公斤25000美元,在1000万治疗年时为每公斤10000美元。

临床怎么用

  • 作者认为来那帕韦上市时可通过大规模生产将价格控制在每人每年100美元以下。
  • 作者指出实现这些低价需要自愿许可和多家供应商,该机制已在其他抗逆转录病毒药物中应用。
  • 作者指出迄今吉利德尚未与药品专利池就来那帕韦达成自愿许可。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite improvements in treatment and oral pre-exposure prophylaxis (PrEP) access, 1.3 million people acquired HIV in 2022. Six-monthly lenacapavir PrEP could benefit tens of millions of people at high risk of infection. However, prices are currently up to $44 819 per person per year (pppy). OBJECTIVES: We projected minimum lenacapavir pricing based on generic mass production and a Cost-Plus (Cost+) model. METHODS: Current active pharmaceutical ingredient (API) and key starting materials (KSMs) costs were obtained from export databases. The routes of synthesis (ROS) were analysed to project a cost of goods (COGs). Formulation, vials and profit margin costs were included using standardized algorithms and Cost+ pricing. We estimated prices with scale-up to supply 1 million then 10 million treatment-years, comparing this with national list prices. RESULTS: The lenacapavir API is currently exported from India for $64 480/kg on 1 kg scale. Based on the ROS and KSMs, API COGs of $25 000/kg and $10 000/kg are achievable for a committed demand of 1 million (2 million tonnes/annum of API) and 10 million treatment-years, respectively. Including formulation steps, injectable lenacapavir could be mass produced for approximately $94 pppy for 1 million and $41 for 10 million treatment-years, if voluntary licences are in place and competition between generic suppliers substantially improves. Greater scale-up with improvements in manufacturers' ROS could reduce prices further. Currently lenacapavir costs $25 395-44 819 pppy. CONCLUSIONS: Lenacapavir could be mass produced for <$100 pppy at launch. Voluntary licensing and multiple suppliers are required to achieve these low prices. This mechanism is already in place for other antiretrovirals. To date, Gilead has not agreed lenacapavir voluntary licences with the Medicines Patent Pool.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Hill A, Levi J, Fairhead C, et al. Lenacapavir to prevent HIV infection: current prices versus estimated costs of production. J Antimicrob Chemother. 2024. PMID: 39225016. doi:10.1093/jac/dkae305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。